Gilead sinks after HCV sales miss estimates

Gilead Sciences Inc. (NASDAQ:GILD) lost $8.79 to $88.21 on Friday after reporting earning that missed analyst estimates, in part due to lower than expected revenue from HCV drug Harvoni ledipasvir/ so...